['small cell lung cancer']
['apatinib']

        Inclusion Criteria:

        Histologic or cytologic diagnosis of small cell lung caner(SCLC), Extensive Stage.

        Previous treatments including first-line therapy with EP or CE and second-line therapy with
        topotecan; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; Males or
        females between 18 Years to 75 Years. Expected survival is above three months. At least one
        measurable lung tumor lesion (according to RECIST criteria, the application of conventional
        technology, diameter length of the lesion >= 20mm or spiral CT >=10mm).

        Adequate hematologic (Leukocyte count >= 4.0×109/L, neutrophil count>=2.0×109/L,
        hemoglobin>=95g/L, platelets>=100×109/L), hepatic function (aspartate transaminase (AST) &
        alanine transaminase(ALT) =<upper normal limit(UNL) x1.5, bilirubin level =< UNL x 1.5).

        Patient can take oral medicine. Patients have the ability to understand and voluntarily
        sign the informed consent, and allow adequate follow-up.

        Exclusion Criteria:

        History of cardiovascular disease: congestive heart failure (CHF) > New York Heart
        Association (NYHA) II, active coronary artery disease(patients with myocardial infarction
        six months ago can be recruited), arrhythmias need to be treated (allow taking beta
        blockers or digoxin).

        Serious clinical infection (> NCI-CTCAE version 4.0 ,infection standard II). Patients with
        epilepsy who need to take medicine (such as steroids or anti epilepsy agents).

        The patients had accepted allogeneic organ transplantation. Bleeding tendency or
        coagulation disorders. Patients who need renal dialysis. Suffered from other tumor within 5
        years( Except: cervical carcinoma in situ, cured basal cell carcinoma, cured bladder
        epithelial tumor).

        Uncontrolled hypertension (systolic pressure>150 mmHg , or diastolic pressure> 90 mmHg).

        Thrombosis or embolism(cerebrovascular accidents including transient ischemic attack within
        the last 6 months).

        Pulmonary hemorrhage >CTCAE grade 2 within 4 weeks before first use of drugs. Other organ
        hemorrhage >CTCAE grade 3 within 4 weeks before first use of drugs. severe uncured wounds,
        ulcers or fracture. uncured dehydration. Factors influencing the safety and compliance of
        patients. Inability to comply with protocol or study procedures. Pregnant or
        breast-feeding. The researcher believe that the Patient is not suitable to participate in
        the study.
      